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Abstract
Background: The autoimmune destruction of exocrine glands that defines primary Sjögren's
syndrome (1SS) often extends to non-exocrine organs including the liver. We aimed to determine
the prevalence of liver disease in patients with 1SS and to evaluate the association of this
complication with other non-exocrine features and serologic markers of autoimmunity and
systemic inflammation.
Methods: We reviewed 115 charts of patients with 1SS and further analyzed the 73 cases that
fulfilled the European Epidemiology Center Criteria, seeking evidence for clinical and subclinical
liver disease.
Results: Liver function tests had been determined in 59 of the 73 patients. Of those, 29 patients
(49.1%) had abnormal liver function tests including 20.3% with clinically overt hepatic disease. Liver
disease was the most common non-exocrine feature in this cohort. Risk factors for abnormal liver
function tests were distributed similarly between the patients with and without liver disease. In 60%
of patients with abnormal liver function tests no explanation for this complication was found except
for 1SS. Liver involvement was significantly more common in 1SS patients who also had evidence
of lung, kidney and hematological abnormalities. Patients with abnormal liver function tests were
also more likely to have an elevated sedimentation rate and a positive anti-ENA during the course
of their disease.
Conclusion: Liver involvement is a common complication in 1SS. Its presence correlates with
systemic disease. We consider that this complication should be routinely sought in patients with
1SS, especially when a positive anti-ENA or evidence of systemic inflammation is found.
Background
Primary Sjögren's syndrome (1SS) is a systemic autoim-
mune disorder characterized by dry eyes (keratoconjunc-
tivitis sicca), dry mouth (xerostomia) as well as
involvement of other exocrine glands. While 1SS is typi-
cally considered an autoimmune exocrinopathy, the im-
mune destruction can often extend to affect non-exocrine
organs. Around 25 % of patients with 1SS can present
with involvement of other organs such as the thyroid, cen-
tral nervous system, lungs, kidney and liver. The associa-
tion of liver disease and 1SS was suggested more than 40
years ago [1]. While liver involvement in 1SS has been
considered "rare" [2] only a few clinical studies specifical-
ly address this complication and evaluate the association
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1SS [3–6].
Liver diseases associated with 1SS include primary biliary
cirrhosis (PBC)-autoimmune cholangitis [8–10], autoim-
mune hepatitis [5,6], viral hepatitis (B and C) [11–21],
sclerosing cholangitis [22], and nodular regenerative hy-
perplasia [23]. In addition, chronic lymphocytic sialaden-
itis has been found in patients with different types of liver
cirrhosis [16–24].
We report the results of a review of cases undertaken to de-
termine the prevalence of abnormal liver function tests
(LFTs) and liver disease in patients with 1SS referred to a
tertiary care center and the association of abnormal LFTs
with other systemic features and autoimmunity markers
of 1SS.
Methods
A total of 115 charts of patients seen at the University of
Michigan Medical Center between 1968 and 1996 were
reviewed and those that had been coded as Sjögren's syn-
drome were considered for analysis. Patients were cap-
tured from the Rheumatology outpatient clinic, the
Rheumatology consults records, different in-patient serv-
ices and also, through the review of the salivary gland bi-
opsies performed at this institution during those years.
Of these 115 patients, we included only those patients
who fulfilled the European Epidemiology Center Criteria
(EECC) for 1SS [26,27]. We also excluded patients with
evidence of other connective tissue diseases, since this
would make them be considered secondary SS. Of the 115
charts reviewed, 73 cases (55 women and 18 men, median
age 53) fulfilled EECC for 1SS and were initially included
for analysis. We reviewed each chart for any record of non-
exocrine manifestations of the disease (Table 1), clinical
and laboratory evidence of liver disease. We considered
patients to have clinically significant liver disease when
the following symptoms and signs were present in associ-
ation with abnormal liver function tests: jaundice, ascites,
spider angiomata, liver palms, palmar erythema, gyneco-
mastia, loss of hair, reduction in testicular size, evidence
of collateral circulation, asterixis, pruritus secondary to
cholestasis, light-colored stools, dark urine, abdominal
pain, hepatomegaly, other signs of portal hypertension in-
cluding esophageal varices and splenomegaly.
Laboratory studies reviewed included: a) liver function
tests (aspartame amino-transferase (AST), alanine-amino
transferase (ALT), alkaline phosphatase (AP), gamma-
glutamyl transpeptidase (GGTP), bilirubins, albumin,
prothrombin time); b) serological markers of autoimmu-
nity (antinuclear antibodies (ANA), antibodies to extract-
able nuclear antigens (ENA), rheumatoid factor (RF),
anti-dsDNA (anti-double stranded DNA), cryoglobulins,
anticardiolipin antibodies (ACL), anti-neutrophil cyto-
plasmic antibodies (ANCA); c) specific markers of au-
toimmune liver disease (antimitochondrial (AMA), anti-
smooth muscle (ASM) and liver-kidney microsomal anti-
bodies); d) viral hepatitis markers (A, B, C); e) liver imag-
ing studies (abdominal ultrasound, abdominal CT,
nuclear medicine studies) ; f) when available, results of
liver biopsies.
Subclinical liver disease was considered present when ab-
normal LFTs (aminotransferases, alkaline phosphatase,
GGT or bilirubin) were detected but no clinical signs,
symptoms or other laboratory findings of liver dysfunc-
tion were found. In addition, we searched for any men-
tion of drug use (immunosuppressive, NSAIDS or others),
transfusions, tobacco use and abuse of alcohol or drugs, as
well as their association with the onset of abnormal liver
function tests.
Table 1: Non-exocrine clinical features considered part of 1SS for this study (excluding liver)
1 Lung Lymphocytic interstitial pneumonia, fibrosing alveolitis, pseudol-
ymphoma, lymphoma, pulmonary amyloidosis
2 Renal Renal tubular acidosis type I, nephrogenic diabetes insipidus, 
chronic interstitial nephritis, immune-mediated glomerulonephri-
tis
3 Cardiovascular Myocarditis, pericarditis, pericardial effusion, Raynaud's
4 Gastrointestinal Atrophic gastritis, pancreatitis
5 Vasculitis Mononeuritis multiplex, axonal neuropathy, purpura
6 Hematologic Coombs positive hemolytic anemia, leukopenia, lymphopenia, 
thrombocytopenia, hypoplasic bone marrow
7 Peripheral nervous system Axonal neuropathy, mononeuritis multiplex
8 Central nervous system Aseptic meningitis, cerebral vasculitis, CVA, TIAs, multiple scle-
rosis "like" changes
9 Endocrine Autoimmune thyroid disease
10 Musculoskeletal Arthritis, arthralgias, myositis
CVA: central vascular accident TIA: transient ischemic attackPage 2 of 9
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The statistical analysis included descriptive measures
(means, standard deviations and ranges). Comparison of
results of patients with and without liver disease was done
using t-tests of continuous variables and Fisher's exact test
or x2 for categoric measures.
Results
Of the 115 charts reviewed, 73 cases (55 women and 18
men, median age 53) fulfilled EECC for 1SS and were in-
itially included for analysis. Of the 73 patients, a 54% of
them (40 patients) have had a salivary gland biopsy per-
formed. In all these patients, the biopsy confirmed the di-
agnosis of Sjögren's syndrome. All patients studied had
objective evidence of 1SS, including keratoconjunctivitis
sicca, positive labial salivary gland biopsy, autoantibodies
and/or salivary gland hypofunction. We excluded those
patients without these objective criteria of 1SS and also
those who did not fulfill EECC criteria.
The mean age at time of onset of disease was 45  20.5
years old and disease duration was 4.9 years  4.5 years
(mean  range). Liver function tests had been determined
in 59 patients (80.8 %) and abnormal liver function tests
were found in 29 of the 59 patients (49.1 %). Further
analysis was then undertaken in those patients in whom
LFTs had been measured. The clinical and laboratory char-
acteristics of these patients are shown in Tables 2 and 3.
Table 2: Clinical characteristics of the patients studied
ORGAN (# of patients) n = 59 FREQUENCY N (%)
Exocrine features (59) 59(100)
* Xerostomia or xerophtalmia
Liver
* Abnormal liver function tests (29) 29 (49.1)
* Physical findings of liver disease (12)
Lung
* LIP (6) 16 (27.1)
* Amyloid (1)
* Other ILD (9)
Heart
* Pericarditis (2) 4 (6.7)
* Myocarditis (2)
CNS
* CNS vasculitis (4) 22 (37.2)
* Aseptic meningitis (4)
* MS "like " disease (3)
* Transverse myelitis (2)
* CVAs, TIAs (9)
PNS
* Peripheral neuropathy (16) 25 (42.3)
* Mononeuritis multiplex (8)
* Myopathy (1)
Kidney
* Tubular disorders (12) 21 (35.5)
* Glomerulonephritis (4)
* Others (5)
Skin 23 (38.9)
Raynaud's 15 (25.4)
Vasculitis 18 (30.5
Blood
* BM hypoplasia (2) 22 (37.2)
* Hemolytic anemia (3)
* Autoimmune thrombocytopenia (4)
* Leukopenia (4)
* Prothrombotic states (3)
* Lymphadenopathy (6)
Arthritis and arthralgias (20) 20 (33.8)
LIP: lymphocytic interstitial pneumonia ILD: interstitial lung disease MS: multiple sclerosis CNS: central nervous systemPage 3 of 9
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common than any other potential non-exocrine features
of SS. Clinical evidence of liver disease, defined in meth-
ods section, was found in 12 patients (20.3%), all of
whom had abnormal liver function tests. Two deaths oc-
curred in the population studied, both attributed to liver
failure. An additional patient required a liver transplant.
In all cases, the diagnosis of 1SS antedated the onset of
liver disease or its diagnosis. Markers of viral hepatitis,
sought in 39 patients, were found only in 4. Two patients
carried the surface antigen of hepatitis B virus and one had
antibodies to hepatitis C virus. In a liver biopsy of a pa-
tient who lacked serological markers for hepatitis viruses,
hepatitis B virus was detected by in situ hybridization.
Risk factors for liver disease were identified in 40% of the
patients with abnormal liver function tests and are de-
scribed in Table 4. No association with tobacco use was
found. Only 5 patients had documented evidence of to-
bacco consumption. We found no significant differences
in risk factors for abnormal liver function tests among pa-
tients with or without hepatic involvement. Therefore, in
60% of the patients with sub clinical or clinical evidence
of liver disease, no clear explanation for the abnormal
LFTs was found, except for the association with 1SS.
The pattern of biochemical liver abnormalities was main-
ly hepatocellular (defined as predominant increase of AST
and/or ALT in comparison with AP and/or bilirubins) in
11 cases; cholestatic (defined as predominant increase in
AP and/or bilirubins compared with AST and/or ALT) in 3
and mixed (evidence of both cholestatic and hepatocellu-
lar damage) in 8 cases. Abnormalities were persistent
(present on every occasion when measured more than
once) in 19 patients (65.5% of those with abnormal
LFTs), intermittent (presence of LFT abnormalities was
not found in all determinations) in 9 (31%) and in one
case (3.5%) there was only one determination of liver
Table 3: Autoimmunity markers of the patients studied
MARKER FREQUENCY n (%)Total = 59 Mean  SEM
 WESR 27 (45.7) 45  10 mm/hr
 CRP 13 (22) 1.5  0.6 mg/dl
+ANA 43 (72.8)
+RF 27 (45.7) 65  10 IU/ml
+ANCA 7 (11.9)
+ENA 27 (45.7)
+ANTI-DSDNA 9 (15.2) 12  5 IU/ml
+CRYOGLOBULINS 2 (3.3)
+ACL 7 (11.8) 25  3 GPL
WESR: Westegren erythrocyte sedimentation rate CRP: C-reactive protein ANA: antinuclear antibodies RF: Rheumatoid factor ANCA: anti-neu-
trophil cytoplasmic antibody ENA: extracted nuclear antigens Anti-dsDNA: anti-double stranded DNA (by Farr assay) ACL: anticardiolipin antibody
Table 4: Risk factors
RISK FACTOR W/LIVER DISEASE W/O LIVER DISEASE P
AGE 55  10 years 53  15 years 0.7
MALE SEX 7/29 8/30 1
FEMALE SEX 22/29 22/30 1
ALCOHOL ABUSE 2/29 3/30 1
VIRUS 5/20 0/11 0.13
DRUGS
* STEROIDS 15/29 13/30 0.606
* CYCLOPHOSPHAMIDE 3/29 5/30 0.706
* AZATHIOPRINE 4/29 3/30 0.706
* HYDROXYCHLOROQUINE 9/29 4/30 0.125
* NSAIDS 15/29 14/30 0.705Page 4 of 9
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is shown in Figure 1. None of the patients with abnormal
liver function tests had clinical evidence of muscle in-
volvement that could explain the high levels of amino-
transferases. Activity of CPK or aldolase was not elevated
when measured in 15 of the 29 patients with abnormal
liver function tests. Anti-mitochondrial antibodies (AMA)
and anti-smooth muscle antibodies (ASMA) were sought
in 5 patients, with positive ASMA in 2.
The association of abnormal liver function tests with oth-
er non-exocrine features of 1SS is shown in Figure 2. Pa-
tients with abnormal liver function tests were more likely
to have lung, kidney or hematological manifestations,
when compared to Sjögren's patients without liver dis-
ease. Presence of other non-exocrine features of 1SS was
not influenced by prevalence of liver diseases.
Regarding laboratory test results, patients with liver dis-
ease were more likely to have an elevated sedimentation
rate at some point during the course of their disease. A
positive anti-ENA (anti-Ro, anti-Ro/La, and/or anti-RNP)
was also associated with an increased prevalence of abnor-
mal liver function tests (Figure 3). The sample was too
small to determine whether a specific ENA was associated
with liver disease. Other markers of systemic inflamma-
tion or autoimmunity did not correlate with the presence
or absence of LFT abnormalities.
Figure 1
Liver function test values in Sjögren's patients with and without liver involvement. AP = alkaline phosphatase, AST
= aspartate amino transferase, ALT = alanine amino transferase. Results represent mean  range, * p < 0.05, n = 59 patients,
with liver disfunction n = 29; without liver diysfunction n = 30
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chronic active hepatitis (3), cryptogenic cirrhosis (2), and
one case each of post-viral cirrhosis, alcoholic hepatitis,
and autoimmune hepatitis.
Discussion
In this group of Sjögren's patients seen at a tertiary care
center, abnormal liver function tests were found to be a
common non-exocrine feature of 1SS. The prevalence of
this association was found to be higher in our study than
in other previous series [2–7]. The true prevalence could
be even higher since liver enzyme profiles were not done
in all patients. The prevalence suggested in previous re-
ports ranges from 6 to 58 %, but the definition of hepatic
disease varies from the unspecific (e.g. hepatomegaly) to
well proven cases of liver disease [1–7,28]. Denko in 1960
reported that 12% of patients with SS had hepat-
osplenomegaly [29]. Other studies done in the 1960's
also confirmed hepatomegaly in 18–20% of patients with
SS [30,31]. In 1970, Whaley reported liver disease in 6%
of patients with SS and mentioned an association with
anti-mitochondrial antibodies [2]. In 1986, Tsianos and
co-workers described 22 SS patients with gastrointestinal
complications, called from a large cohort; only two pa-
tients had liver disease, each with chronic active hepatitis
[4]. Other studies have reported variable prevalence [3,28]
and different histopathological findings in liver biopsies
ranging from cholestatic liver damage (stage I primary bil-
iary cirrhosis) to chronic active hepatitis due to hepatitis
C virus.
Figure 2
Association of liver disease with other extraglandular manifestations in patients with Sjögren's syndrome. Fig-
ure represents percentage of patients with and without liver disease who presented with other non-exocrine features of 1SS.
Patients with liver disease = 29; patients without liver disease = 30, * p < 0.05.
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BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/21In our study, liver disease was associated with other non-
exocrine manifestations of 1SS, specifically those affect-
ing lung, kidney and blood cells. Those patients with se-
rological evidence of systemic inflammation, as shown by
an elevated sedimentation rate, were more likely to have
liver test abnormalities. Also, the presence of a positive
anti-ENA correlated positively with hepatic disease. An as-
sociation of ENA response with liver disease has been de-
scribed in children with autoimmune hepatitis, where
anti-ENA-positive patients demonstrated more severe liv-
er test abnormalities than those who were anti-ENA-nega-
tive [32]. In another study, a 15 % of patients with various
chronic liver diseases were found to be anti-RNP positive
[33].
With etiopathogenesis of 1SS still an open question [34],
a possible role of hepatitis C virus (HCV) has drawn atten-
tion. Recent studies have mentioned HCV incidence in pa-
tients with 1SS ranging from 14–19% [11,12,16,18,21].
Phenotypic characterization of the minor salivary glands
with immunohistochemistry in patients with hepatitis C
virus infection and/or 1SS has given conflicting results
[14,15] Some reports mention that the salivary gland
findings are strikingly similar in patients with liver disease
associated with HCV infection than in those with 1SS
[12], while others mention distinctive differences between
both groups regarding focus score, expression of surface
markers in lymphocytes infiltrating the salivary glands
and in epithelial cells, as well as differences in the degree
of inflammation [14,15]. Transgenic mice models that
Figure 3
Association of liver disease with laboratory abnormalities in patients with Sjögren's syndrome. Figure represents
percentage of patients with and without liver disease who presented with serological evidence of autoimmunity or inflamma-
tion. Patients with liver disease = 29; patients without liver disease = 30, * p < 0.05.
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affecting salivary and lachrymal glands [19]. Expression of
autoimmunity markers also tends to differ between HCV-
infection and 1SS. Positive ENAs are rarely seen in HCV-
patients. Also, in most cases sicca symptoms are not
present in individuals with HCV as compared with the
1SS population. Although the prevalence of viral hepati-
tis markers in our group of patients with liver disease was
very low and did not account for most of the cases with
abnormal liver function tests, these markers were not
sought in a small percentage of these patients. It is impor-
tant to note that HCV appears to account for a subgroup
of patients with exocrine complaints in which half the cas-
es might meet the definition for SS according to European
and Manthorpe criteria. However, this subgroup is charac-
terized by the absence of clinical manifestations observed
in 1SS, and the absence of anti-Ro and anti-La [35].
An aberrant interaction between lymphocytes and differ-
ent epithelial tissues has been proposed as a mechanism
for the damage seen in different organs in 1 SS [36]. Since
it has been suggested that the target tissue involved in the
autoimmune histopathologic lesions of 1SS might be the
epithelium [37], it is interesting that the findings in our
study point to the association of liver disease with pulmo-
nary and renal abnormalities, all which are characterized
by epithelial damage [38,39]. Epithelial cells have been
proposed to be active participants rather than passive tar-
gets in the chronic immune response in 1SS but further
studies are needed to establish the role of liver epithelial
cells in the pathogenesis of hepatic damage in this disease,
including the analysis of HLA expression and cytokine se-
cretion pattern in these cells.
The co-existence of liver disease and the presence of circu-
lating AMAs in Sjögren's patients sera has been pointed as
an indicator that liver pathology might be autoimmune
and similar to that of primary biliary cirrhosis [4,7,8,10].
In previous studies, a pericholangial lymphocytic infiltra-
tion similar to that found in stage I of primary biliary cir-
rhosis, has been reported in 1SS with abnormal liver
function tests or positivity for AMA [4,7]. In our review of
cases, we found predominance in hepatocellular liver
damage rather than cholestatic disease, which would ar-
gue against a PBC-type of liver damage. Other authors had
proposed that SS associated with PBC should be consid-
ered a form of secondary SS that resembles more the "sicca
complex" with exocrine features seen in patients with
rheumatoid arthritis [40,41].
Limitations of the study come primarily from being a ret-
rospective analysis. Since the patients were studied in a
tertiary care referral center, the severity of the disease and
the prevalence of the manifestations might be different
from the general 1SS population. Furthermore, in many
cases, Sjögren's syndrome diagnosis had been sought be-
cause of otherwise unexplained non-exocrine features.
While we could not find an association between use of
NSAIDS or other medications and prevalence of liver
function tests abnormalities, the study design did not al-
low us to exclude the possibility of over-the-counter
(OTC) medication use that could have affected LFT's
measurement. Drug toxicity is certainly an important fac-
tor to be considered. However, given that most patients
had persistent rather than intermittent abnormalities of
LFTs and that the use of hepatotoxic drugs was not elicited
in the majority of patients with liver abnormalities, a toxic
effect of medications could not be established.
Conclusions
Based on the results of this study, we consider that an eval-
uation for clinical and serological evidence of liver disease
should be done in every patient with 1SS, particularly if
there is evidence of other non-exocrine complications or
serological evidence of systemic inflammation. Although
no other diagnosis explaining liver disease may be found,
the disorders for which treatment might be beneficial (e.g.
immunosuppressants for autoimmune hepatitis, interfer-
on-alpha for viral hepatitis, ursodeoxycolic acid for pri-
mary biliary cirrhosis) warrant a diligent search in all cases
of 1SS with abnormal liver function.
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